Vaxcyte (PCVX) Return on Capital Employed (2020 - 2026)
Vaxcyte's (PCVX) quarterly Return on Capital Employed came in at 37.11% in Q1 2026, down 1812.0% year-on-year from 2.17% in Q1 2025, and down 15.78% on a QoQ basis from 32.06% in Q4 2025.
Vaxcyte (PCVX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Vaxcyte (PCVX) has 7 years of Return on Capital Employed data on file, last reported at 37.11% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 1812.0% year-over-year to 37.11% in Q1 2026; TTM through Mar 2026 was 37.11%, a 1812.0% decrease from a year earlier, with the FY2025 full-year figure at 30.27%, down 572.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 37.11%, down from 32.06% in the prior quarter.
- Over the last five years, Return on Capital Employed for PCVX reached as high as 16.77% in Q4 2024 and fell as low as 47.12% in Q3 2022.
- Historically, Return on Capital Employed has averaged 29.75% across 5 years, with a median of 28.77% in 2024.
- Across the five-year window, Return on Capital Employed surged 2180 bps in 2023 and plunged 1812 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 34.74% in 2022, then declined by 3 bps to 35.82% in 2023, then surged by 53 bps to 16.77% in 2024, then tumbled by 91 bps to 32.06% in 2025, then retreated by 16 bps to 37.11% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 37.11% in Q1 2026, 32.06% in Q4 2025, and 26.71% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Vaxcyte | 7.76 Bn | 7.76 Bn | - | -37.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.11% |
| Dec 31, 2025 | -32.06% |
| Sep 30, 2025 | -26.71% |
| Jun 30, 2025 | -22.25% |
| Mar 31, 2025 | -18.99% |
| Dec 31, 2024 | -16.77% |
| Sep 30, 2024 | -22.37% |
| Jun 30, 2024 | -28.77% |
| Mar 31, 2024 | -30.76% |
| Dec 31, 2023 | -35.82% |
| Sep 30, 2023 | -25.32% |
| Jun 30, 2023 | -25.39% |
| Mar 31, 2023 | -27.68% |
| Dec 31, 2022 | -34.74% |
| Sep 30, 2022 | -47.12% |
| Jun 30, 2022 | -38.20% |
| Mar 31, 2022 | -35.61% |
| Dec 31, 2021 | -33.39% |
| Sep 30, 2021 | -30.23% |
| Jun 30, 2021 | -26.60% |